Balyasny Asset Management
CBIO

Balyasny Asset Management’s Crescent Biopharma CBIO Stock Holding History

Balyasny Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,500
Closed -$183K – 2896
2024
Q2 		$183K Buy
6,500
+3,201
+97% +$333K ﹤0.01% 2351
2024
Q1 		$990K Buy
+3,299
New +$985K ﹤0.01% 1797

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Balyasny Asset Management's CBIO Position: Q1 2026 in Review

Balyasny Asset Management increased its Crescent Biopharma (CBIO) stake by 1,252% in Q1 2026, buying an estimated $16.1M and bringing the position to 1,510,033 shares worth $27.7M. The position accounts for 0.04% of the portfolio, ranked #558.

Balyasny Asset Management first reported a position in CBIO in Q1 2018 and has held it in 5 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Balyasny Asset Management held 1,510,033 shares of Crescent Biopharma worth $27.7M as of Q1 2026.
  • Balyasny Asset Management bought 1,398,318 Crescent Biopharma shares in Q1 2026, an estimated $16.1M.
  • Crescent Biopharma made up 0.04% of Balyasny Asset Management's portfolio in Q1 2026, its #558 holding.
  • Balyasny Asset Management first reported a position in Crescent Biopharma in Q1 2018 and has held it in 5 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.